Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024
The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D.
- The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D.
- Meanwhile, the first Phase 3 study results of mazdutide in the weight loss of overweight/obese subjects (GLORY-1) were reported in oral presentation session of EASD.
- Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks.
- I look forward to the clinical availability of mazdutide as soon as possible to provide new treatment options for patients with type 2 diabetes."